Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Austria.
Am J Kidney Dis. 2011 Mar;57(3):403-14. doi: 10.1053/j.ajkd.2010.10.047. Epub 2010 Dec 24.
We have previously shown that plasma aldosterone levels within the physiologic reference range predicted increased all-cause and cardiovascular disease (CVD) mortality in patients referred for coronary angiography. Decreased kidney function is associated with a marked increase in CVD mortality that is not explained fully by known cardiovascular risk factors. We hypothesized that level of kidney function might modify the association between plasma aldosterone level and CVD mortality.
Prospective cohort study.
SETTING & PARTICIPANTS: 3,153 patients (mean age, 62.7 ± 10.6 years; 30.1% women) free of primary kidney disease at baseline were referred for coronary angiography in a tertiary-care center in Southwest Germany between 1997 and 2000.
Plasma aldosterone level, determined using radioimmunoassay. Tertiles of estimated glomerular filtration rate (eGFR) based on creatinine and cystatin C levels.
OUTCOMES & MEASUREMENTS: CVD mortality and sudden cardiac death events at 7.75 years.
At baseline, median plasma aldosterone concentration was 79.0 (25th-75th percentile, 48.0-124.0) pg/mL. Mean eGFR was 83.8 ± 20.1 (SD) mL/min/1.73 m(2), and mean eGFRs in tertiles 1-3 were 61.9 ± 13.0, 84.7 ± 4.4, and 104.7 ± 10.3 mL/min/1.73 m(2), respectively. After a median follow-up of 7.75 years, 454 (14.4%) patients died of cardiovascular causes and 179 (5.7%) died suddenly. Multivariate Cox proportional hazard analyses showed increased risks of CVD mortality (HR per 50-pg/mL increment in plasma aldosterone concentration, 1.08; 95% CI, 1.03-1.12; P = 0.001) and sudden cardiac death (HR, 1.11; 95% CI, 1.06-1.15; P < 0.001). In tertiles 1-3 of eGFR, adjusted HRs per 50-pg/mL increment in plasma aldosterone concentration for CVD mortality were 1.10 (95% CI, 1.05-1.14; P < 0.001), 1.00 (95% CI, 0.83-1.16; P = 0.8), and 0.97 (95% CI, 0.75-1.26; P = 0.8), respectively (product term for interaction, P = 0.001), and for sudden cardiac death were 1.13 (95% CI, 1.08-1.17; P < 0.001), 0.99 (95% CI, 0.75-1.29; P = 0.9), and 0.90 (95% CI, 0.60-1.34; P = 0.5), respectively (product term for interaction, P < 0.001).
No urinary analysis was performed to assess dietary salt intake and proteinuria.
Our findings suggest that the association of higher plasma aldosterone concentration with overall CVD mortality and sudden cardiac death is stronger for patients with lower kidney function.
我们之前的研究表明,在生理参考范围内的血浆醛固酮水平与接受冠状动脉造影检查的患者的全因和心血管疾病(CVD)死亡率增加有关。肾功能下降与 CVD 死亡率显著增加有关,而这一现象不能完全用已知的心血管危险因素来解释。我们假设肾功能水平可能会改变血浆醛固酮水平与 CVD 死亡率之间的关系。
前瞻性队列研究。
3153 名患者(平均年龄 62.7±10.6 岁,30.1%为女性)在德国西南部的一家三级医疗中心接受冠状动脉造影检查时无原发性肾脏疾病,研究时间为 1997 年至 2000 年。
采用放射免疫法测定血浆醛固酮水平。基于肌酐和胱抑素 C 水平估算的肾小球滤过率(eGFR)的三分位数。
7.75 年时的 CVD 死亡率和心源性猝死事件。
基线时,中位血浆醛固酮浓度为 79.0(25 至 75 百分位,48.0 至 124.0)pg/mL。平均 eGFR 为 83.8±20.1(SD)mL/min/1.73 m2,eGFR 的三分位数 1-3 分别为 61.9±13.0、84.7±4.4 和 104.7±10.3 mL/min/1.73 m2。中位随访 7.75 年后,454 名(14.4%)患者死于心血管原因,179 名(5.7%)死于心源性猝死。多变量 Cox 比例风险分析显示,血浆醛固酮浓度每增加 50pg/mL,CVD 死亡率的风险增加(HR,1.08;95%CI,1.03-1.12;P=0.001)和心源性猝死(HR,1.11;95%CI,1.06-1.15;P<0.001)。在 eGFR 的三分位数 1-3 中,血浆醛固酮浓度每增加 50pg/mL,CVD 死亡率的调整 HR 分别为 1.10(95%CI,1.05-1.14;P<0.001)、1.00(95%CI,0.83-1.16;P=0.8)和 0.97(95%CI,0.75-1.26;P=0.8)(交互项乘积,P=0.001),心源性猝死的调整 HR 分别为 1.13(95%CI,1.08-1.17;P<0.001)、0.99(95%CI,0.75-1.29;P=0.9)和 0.90(95%CI,0.60-1.34;P=0.5)(交互项乘积,P<0.001)。
没有进行尿分析来评估膳食盐摄入量和蛋白尿。
我们的研究结果表明,对于肾功能较低的患者,较高的血浆醛固酮水平与全因 CVD 死亡率和心源性猝死之间的关联更强。